BCL2 related protein A1Genealiases: ACC-1 · ACC-2 · ACC1 · ACC2 · BCL2L5 · BFL1
Q-omics provides the consensus-scored BCL2A1 profile across patient tissues and cancer cell-line models. BCL2A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BCL2A1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, BCL2A1 RNA expression shows 25,111 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where BCL2A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL2A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL2A1 survival associations across molecular data types. BCL2A1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL2A1 RNA expression–survival associations across cancer types. High BCL2A1 expression shows unfavorable associations in ACC, KIRC, LAML, LGG and UVM, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for BCL2A1 RNA expression.
This table summarizes BCL2A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BCL2A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL2A1 shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, KIRP, HNSC and STAD. The KIRC box plot shows higher BCL2A1 RNA expression in tumor versus normal tissue (log2 FC = +2.404, t-test p < 0.001).
This table shows molecular features associated with BCL2A1 in patient tissues and cancer cell lines. In patient samples, BCL2A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL2A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
